Table 1:
Characteristics of the autotransplant CIBMTR cohorts for Hodgkin (HL), non-Hodgkin (NHL) lymphoma and plasma cell myeloma (PCM)
| Diagnosis | |||
|---|---|---|---|
| Characteristics | HL | NHL | PCM |
| Subjects (n) | 916 | 3546 | 4566 |
| Centers (n) | 103 | 118 | 118 |
| Median age at transplant (y; range) | 35(18-77) | 56(18-82) | 58(22-80) |
| 18 - 29 | 328(36) | 147(4) | 15(<1) |
| 30 - 39 | 255(28) | 307(9) | 152(3) |
| 40 - 49 | 166(18) | 708(20) | 756(17) |
| 50 - 59 | 93(10) | 1094(31) | 1719(38) |
| 60 - 69 | 65(7) | 1098(31) | 1653(36) |
| ≥70 | 9(<1) | 192(5) | 271(6) |
| Male, n (%) | |||
| 528(58) | 2194(62) | 2706(59) | |
| Race/Ethnicity, n (%) | |||
| Caucasian/White | 727(79) | 3140(89) | 3494(77) |
| Others | 184(20) | 384(11) | 1043(23) |
| Unknown/Declined | 5(<1) | 22(<1) | 29(<1) |
| N prior lines of chemotherapy regimens, n (%) | |||
| 1 | 156(17) | 847(24) | 2472(54) |
| 2 | 488(53) | 1425(40) | 1254(27) |
| 3 | 172(19) | 712(20) | 451(10) |
| ≥4 | 72(8) | 416(12) | 205(4) |
| Missing | 28(3) | 146(4) | 184(4) |
| Anthracyclines pre-conditioning, n (%) | |||
| No | 21(2) | 54(2) | 2409(53) |
| Yes | 849(93) | 3180(90) | 1954(43) |
| Missing | 46(5) | 312(9) | 203(4) |
| Alkylating drug pre-conditioning, n (%) | |||
| No | 2(<1) | 22(<1) | 1656(36) |
| Yes | 874(95) | 3338(94) | 2569(56) |
| Missing | 40(4) | 186(5) | 341(7) |
| Etoposide pre-conditioning, n (%) | |||
| No | 214(23) | 1153(33) | 3670(80) |
| Yes | 602(66) | 1964(55) | 592(13) |
| Missing | 100(11) | 429(12) | 304(7) |
| Cyclophosphamide/melphalan pre-conditioning | |||
| No | N/A | 1798(39) | |
| Yes | 2553(56) | ||
| Missing | 215(5) | ||
| Radiation therapy pre-conditioning, n (%) | |||
| No | 451(49) | 2038(57) | 3157(69) |
| Yes | 345(38) | 782(22) | 1259(28) |
| Missing | 120(13) | 726(20) | 150(3) |
| Total body radiation (TBI) conditioning, n (%) | |||
| No | 871(95) | 3034(86) | 4338(95) |
| Yes | 45(5) | 512(14) | 228(5) |
| TBI conditioning dose, n (%) | |||
| None | 871(95) | 3034(86) | 4338(95) |
| ≤10 Gy | 5(<1) | 100(3) | 60(1) |
| >10 Gy | 40(4) | 408(12) | 167(4) |
| Missing | 0 | 4(<1) | 1(<1) |
| Lymphoma conditioning type, n (%) | |||
| TBI-based | 45(5) | 512(14) | N/A |
| BEAM and similar | 577(63) | 2319(65) | |
| CBV and similar | 124(14) | 381(11) | |
| BuMel/BuCy | 87(9) | 197(6) | |
| Others | 83(9) | 137(4) | |
| PCM conditioning type, n (%) | |||
| Melphalan only | N/A | N/A | 3844(84) |
| Melphalan+TBI+/−other | 182(4) | ||
| Melphalan+other (no TBI) | 285(6) | ||
| Bu+ y+/−other | 185(4) | ||
| Others | 70(2) | ||
| Melphalan conditioning dose (mg/m2), n (%) | |||
| None | N/A | N/A | 256(6) |
| 140 | 1430(31) | ||
| 200 | 2660(58) | ||
| Missing | 220(5) | ||
| Median interval diagnosis to transplant (mo; range) | 21(<1−374) | 16(<1−362) | 8(<1−295) |
| <12 | 156(17) | 1323(37) | 3304(72) |
| ≥12 | 758(83) | 2217(63) | 1260(28) |
| Missing | 2(<1) | 6(<1) | 2(<1) |
| Tandem autotransplant, n (%) | |||
| No | 877(96) | 3521(99) | 3806(84) |
| Yes | 39(4) | 25(<1) | 760(17) |
| Year of transplant, n (%) | |||
| 1995-1999 | 338(37) | 1352(38) | 615(13) |
| 2000-2004 | 165(18) | 737(21) | 1244(27) |
| 2005-2010 | 413(45) | 1457(41) | 2707(59) |
| Median follow-up of survivors (mo; range) | 90(3−246) | 110(3−243) | 97(3−236) |
| Kaplan-Meier 5-year survival rate estimates (95% CI) | 67%(64, | 57%(55, | 57(55, |
| 70% | 58%) | 58%) | |
TBI = total body irradiation; BCNU = Bis-chloroethylNitrosourea (i.e. carmustine); BEAM = BCNU, etoposide, cytarabine, and melphalan (Mel); CBV = yclophosphamide, BCNU and etoposide; Bu = Busulfan.